Home Blog Page 886

Sigenergy Inaugurates Nantong Smart Energy Center, Pioneering “AI in All” Strategy and Next-Gen Energy Portfolio

NANTONG, China, March 13, 2026 /PRNewswire/ — Sigenergy today officially inaugurated the Sigenergy Nantong Smart Energy Center in Nantong, Jiangsu Province, China, marking a new milestone in the company’s global development. The event brought together nearly 2,000 guests from more than 50 countries and regions, including founders, CEOs, and senior executives from leading distributors and installation partners worldwide, demonstrating Sigenergy’s rising global influence and leadership in innovation.

Sigenergy inaugurated the Sigenergy Nantong Smart Energy Center in Nantong, Jiangsu Province, China
Sigenergy inaugurated the Sigenergy Nantong Smart Energy Center in Nantong, Jiangsu Province, China

During the event, Sigenergy announced a series of landmark developments that signal the company’s next phase of global growth. The company unveiled its “AI in All” strategy, and introduced new products covering residential, commercial and industrial (C&I), and utility-scale applications. Together, these milestones reinforce Sigenergy’s commitment to advancing AI-driven energy innovation, intelligent manufacturing, and full-scenario energy solutions worldwide.

“AI in All”: Bringing Intelligence to the Entire Energy Ecosystem

Sigenergy’s “AI in All” strategy positions artificial intelligence as a core capability embedded across products, software, manufacturing, and energy management systems, transforming energy systems from simply operating to becoming intelligent, collaborative, and continuously optimized.

“Sigenergy is committed to leading the global energy transition through AI-driven innovation,” said Tony Xu, Founder and CEO of Sigenergy. “Our focus is on harnessing AI to create smarter, more adaptive energy systems that set the standard for the industry.”

As renewable energy and storage reshape the global energy landscape, the industry is shifting from hardware-driven competition toward integrated systems defined by user experience. Within this context, Sigenergy embeds AI as a foundational layer across its technology platform. At the product level, AI supports energy management, operational optimization, and dispatch control; through software, it enhances configuration, monitoring, and strategy execution; and at the system level, it connects distributed devices and applications, enabling coordinated and intelligent operations across residential, commercial, and utility-scale scenarios.

With the “AI in All” strategy, Sigenergy is translating AI innovation into tangible product capabilities and system intelligence, accelerating the development of smarter, more adaptive energy infrastructure worldwide.

Nantong Smart Energy Center: A New Benchmark for Intelligent Manufacturing

Supporting the global rollout of the “AI in All” strategy is the newly launched Sigenergy Nantong Smart Energy Center. Covering 136,000 square meters with an investment of RMB 500 million (≈ USD 70 million), the facility has an annual production capacity exceeding 300,000 inverters and battery packs. More than a factory, it serves as an integrated hub combining advanced R&D, intelligent manufacturing, global delivery, and energy management.

At the heart of Sigenergy’s manufacturing network, the Nantong Smart Energy Center features a fully integrated digital platform that enables operators to monitor production in real time and coordinate processes across the facility. Unlike conventional factories relying on isolated automation, Manufacturing Execution Systems (MES), Warehouse Management Systems (WMS), and Energy Management Systems (EMS) are interconnected, allowing material dispatch, equipment configuration, and production adjustments to be automatically synchronized.

Sigenergy maintains industry-leading precision across key manufacturing processes. Automated welding with Charge-Coupled Device (CCD) visual inspection achieves a 99.9% yield rate, Surface-Mount Technology (SMT) lines process components at 0.043 seconds per unit with 20–30 micron accuracy, and Dual In-line Package (DIP) assembly times are cut by 50% through automation and lean practices. AI-powered quality inspections replace manual sampling, while Sigenergy’s three-dimensional intelligent logistics system integrates overhead and ground material movement for optimized efficiency.

This combination of advanced equipment and intelligent systems delivers industry-leading throughput — producing one battery pack every 15 seconds and one inverter every 21 seconds. The launch of the Nantong Smart Energy Center ensures Sigenergy’s original designs are realized at scale with uncompromised quality, establishing a benchmark for precision, consistency, and long-term reliability.

Expanding Full-Scenario Solutions with Three New Product Launches

Sigenergy also unveiled several new products designed to further strengthen its full-scenario energy portfolio, spanning residential, commercial & industrial, and utility-scale applications.

  1. Residential: SigenStor Neo

    For the residential market, the company introduced SigenStor Neo, a new home energy system. Building on Sigenergy’s signature modular architecture and circular light-ring design, the system combines a PV inverter, battery PCS, energy management system, gateway, and battery pack into a single platform.

    Designed for the evolving needs of modern households, SigenStor Neo delivers enhanced system integration, improved coordination across components, and broader compatibility across different home energy scenarios, providing users with a more intelligent, streamlined, and user-friendly energy experience.

  2. C&I PV inverter

    For commercial and industrial applications, Sigenergy launched a 166 kW PV inverter, designed to deliver higher power density and improved system efficiency through advanced power electronics technology. The solution provides enterprise customers with more efficient and reliable solar and storage integration.

  3. Utility inverter

    In the utility-scale segment, Sigenergy introduced a new utility inverter designed for large-scale solar power plants. With a high power density architecture, it delivers up to 500 kW output, supports 1650 V DC input and 1000 V AC systems, helping reduce system costs while improving overall power generation efficiency.

    The inverter features up to 18 MPPTs, each supporting two strings with increased current capacity, enabling higher energy yields in complex terrain. Advanced arc fault circuit interruption (AFCI) technology with detection up to 500 meters, combined with multiple protection mechanisms, enhances operational safety.

    For operations and maintenance, the inverter offers MPPT-level fault detection and intelligent diagnostics, along with remote monitoring, intelligent inspection, and data analytics, helping operators optimize performance and reduce costs. AI capabilities further improve ultra-short-term and short-term power generation forecasts by integrating equipment, site, and weather data, enabling smarter dispatch planning and revenue optimization.

Through this expanded product portfolio, Sigenergy is building a comprehensive energy technology platform spanning residential systems, commercial energy infrastructure, and utility-scale power plants.

NATURE’S MIRACLE HOLDING INC. PROVIDES INVESTOR HOTLINE

ONTARIO, Calif., March 13, 2026 /PRNewswire/ — Nature’s Miracle Holding Inc. (“Nature’s Miracle” or the “Company”) (OTCQB: NMHI), a leader in controlled environment agriculture, today announced that it is setting up an investor hotline at 1-800-816-3223.  This replaces a previously provided number. Or email inquiries to info@nature-miracle.com.

About Nature’s Miracle Holding Inc.

Nature’s Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing equipment and services to the Controlled Environment Agriculture (“CEA”) industry, including vertical farming in North America. Through its two wholly-owned subsidiaries, Visiontech Group, Inc. and Hydroman, Inc., Nature’s Miracle provides grow lights and hydroponic products to hundreds of indoor growers. The Company also maintains a robust pipeline to build commercial-scale greenhouses to meet the growing demand for fresh, local produce in North America. 

Important Information About Press Release

This press release includes information about the MOU. Other than specific provisions in the MOU, the MOU deal points, including the structure of the acquisition and the consideration to be offered, among other things, are not binding. This press release is intended to show the willingness of the parties to fulfill plans that complement their businesses. A transaction is final only upon the signing of a definitive agreement.

This press release contains a phone number for the Company but may not be available 24 hours a day, have limited personnel handling such communications. The Company reserves the right not to reply to harassment type messages and threats.

This press release does not contain all the information that should be considered concerning the stock of Nature’s Miracle, its warrants, and its related businesses. The press release is not intended to form the basis of any investment decision or any other decision in respect to the securities of Nature’s Miracle. More information can be obtained by writing directly to Nature’s Miracle Holding Inc., 3281 E. Guasti Rd.#175., Ontario, CA 91761, attention Investor Information.

Forward-looking Statements

Except for historical information contained herein, this press release contains certain “forward-looking statements” within the meaning of the federal U.S. securities laws with respect to the MOU and business of Nature’s Miracle; other future references such as the anticipated synergies resulting from the transactions contemplated by the MOU,  the services and markets of Nature’s Miracle, our expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities, future plans and intentions, results, level of activities, performance, goals or achievements or other future events. These forward-looking statements generally are identified by words such as “anticipate,” “believe,” “expect,” “may,” “could,” “will,” “potential,” “intend,” “estimate,” “should,” “plan,” “predict,” or the negative or other variations of such statements, reflect our management’s current beliefs and assumptions and are based on the information currently available to our management. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the business and revenue prospects of Nature’s Miracle may not materialize which may adversely affect the price of Nature’s Miracle’s securities; (ii) the occurrence of any unforeseen event that would impact continued listing of Nature’s Miracle’s securities on the Nasdaq exchange; (iii) changes in the competitive industries in which Nature’s Miracle operates, variations in operating performance across competitors, changes in laws and regulations affecting Nature’s Miracle’s business and changes in the combined capital structure; (iv) the ability to implement business plans, forecasts and other expectations after the completion of the proposed transactions contemplated by the MOU; (v) the risk of downturns in the market and Nature’s Miracle’s industry including, but not limited to market prices of indoor grower’s produce, transportation costs, competition with outdoor growers and demand in the consumer marketplace. For additional details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our prospectus/proxy statement included in our Registration Statement on Form S-4 on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and neither Nature’s Miracle assume any obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Nature’s Miracle does not give any assurance that the Company will achieve its expectations.

Non-solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential business combination or any other matter and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Nature’s Miracle, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Esaote at EAU 2026: Introducing Exclusive PAM Technology to Advance Precision in Urological Imaging

The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth

LONDON, March 13, 2026 /PRNewswire/ — Esaote Group, a leading Italian innovator in medical imaging – ultrasound, dedicated magnetic resonance and medical IT, is reinforcing its position as a leading provider of advanced imaging and guided therapy solutions for urologists at the 41st Annual European Association of Urology (EAU) Congress, currently underway in London (13-16 March 2026).

Prostate Attention Map (PAM), Esaote’s new innovative technology dedicated to urology.
Prostate Attention Map (PAM), Esaote’s new innovative technology dedicated to urology.

Esaote presents its new and innovative technology dedicated to urology: the exclusive Prostate Attention Map (PAM), now available on the new MyLab™E85 GTS. Esaote will also present  the new MyLab™C30 GTS, extending high image quality performance on a portable system that allow to meet different examination settings.

Throughout the Congress, Esaote (Booth N16) is showcasing a comprehensive portfolio designed to support diagnosis precision and intervention guidance in prostate care, with a strong focus on confidence, efficiency and clinical excellence. PAM Technology is at the core of this innovation, offering automatic analysis of prostate mpMRI volumes and identifying suspicious regions of interest, therefore assisting urologists on enhancing target guidance and decision making.

“PAM Technology is fully integrated into Esaote’s UroFusion software,“ said Marta Daniel, Guided Therapy Product and Clinical Solutions Manager at Esaote. “Our UroFusion package is designed to provide focal guidance during prostate targeted biopsies. Thanks to A.I., urologists have a seamless workflow, with similar duration as a standard biopsy exam, while improving  confidence and accuracy during their biopsy procedures.”

During the congress Esaote is also actively participating in TP Biopsy and MRI-US Fusion hands-on sessions, guided by internationally recognised specialists and offering attendees the opportunity to experience the latest advances on UroFusion.

Esaote’s presence at EAU 2026 – with the introduction of PAM Technology and the launch of two urology dedicated systems – marks a significant expansion of Esaote’s Guided Therapy Solutions (GTS) line and highlights the Company’s ongoing commitment to empowering urologists with reliable, intelligent and clinically relevant imaging solutions that provide advanced image quality, intuitive interaction and seamless fusion workflows in prostate care.

Esaote Group is a leader in medical imaging (ultrasound, MRI and diagnostic process management software). At the end of 2025, the Group counts 1,300 employees, half of which are based in Italy. With facilities in Genoa and Florence and its own production and research units in Italy and the Netherlands, Esaote is present in over 100 countries worldwide. www.esaote.com

 

Electric Pole Superstar as Vientiane’s New Landmark

A tangled electricity pole in downtown Vientiane has unexpectedly gone viral after being pinned on Google Maps as “Electric Pole Superstar,” drawing curious tourists and dozens of reviews. (Photo credit: Thongsavanh Souvannasane/The Laotian Times).

A heavily tangled electricity pole in downtown Vientiane has recently gone viral online, drawing attention from both locals and foreign visitors curious about the unusual sight.

Located at the four-way intersection of Sethathirath Road and Rue Nokeokoummane near Wat Mixay in Chanthabouly district, the single electricity pole carries not only power lines but also a dense web of fiber-optic cables, internet lines, and other telecommunications wires.

Over the years, the accumulation of different cables on the same pole has created an unusually messy appearance, making it stand out even in a busy city center.

The pole has even been pinned on Google Maps under the name “Electric pole super star.” Although it is unclear who added the location, the listing has quickly attracted attention, gathering more than 40 reviews within just a week.

Many tourists walking through the area are often surprised by the sight and stop to take photos of the pole.

One visitor, George Kalogerak, wrote in a review:

“One of my favourite spots in the city, worth walking by to have a look. Jokes aside, Vientiane is a very nice city, but it’s crazy how many cables you see. This one is the craziest of all!”

Another visitor, Roos Vgn, commented: “Highlight of Vientiane! It really is a super star.”

The humor was not lost on everyone. 

One comment by Souliyo Vongdala humorously suggested that the pole should be nominated as a UNESCO landmark.

While there is no official information about when the pole was first installed, old photos suggest it may have been standing in the area for at least 40 years.

Today, the chaotic cluster of cables has unexpectedly turned the ordinary infrastructure into a quirky attraction, with visitors stopping by to capture what some jokingly call one of Vientiane’s most unusual “soft power” landmarks.

“Hello, Beijing! Diplomatic Memoirs in the Capital” Video Series Launched at London Book Fair 2026

LONDON, March 13, 2026 /PRNewswire/ — The launch event for the “Hello, Beijing! Diplomatic Memoirs in the Capital” video series was successfully held on March 11, 2026, at the London Book Fair.

Premiere of the Video Series“Hello, Beijing! Diplomatic Memoirs in the Capital” in 2026 London Book Fair
Premiere of the Video Series“Hello, Beijing! Diplomatic Memoirs in the Capital” in 2026 London Book Fair

Supported by the Beijing Culture Guiding Fund, the China National Publications Import and Export (Group) Co.,Ltd has officially launched the “Hello, Beijing! Diplomatic Memoirs in the Capital” international dialogue project. The project focuses on Beijing’s development across economic, technological, and cultural sectors, inviting foreign diplomats to share their impressions of Beijing and their stories about China. It aims to present to the world a Beijing that harmoniously blends tradition and modernity, while demonstrating confidence and openness.

The six-episode video series is produced in collaboration with multiple foreign embassies in China. Through interviews and documentary-style filming, each episode tells the story of a diplomat’s life in Beijing. Three episodes have already been released, featuring distinguished guests such as H.E. Sergio Cabrera, Ambassador of Colombia to China; Ms. Isabel Cervera, former Director of the Instituto Cervantes in Beijing; and Mr. Federico Roberto Antonelli, Cultural Counselor of the Italian Embassy.

During the launch, attendees viewed selected clips from the series. The diplomats’ first-hand experiences and personal narratives offered the audience a profound insight into Beijing’s remarkable transformation and cultural inclusiveness. Ms. Lei Jianhua, Vice President of CNPIEC, stated, “This project uses ‘diplomats’ Beijing stories’ as its narrative thread, striving to present a multi-dimensional, rich, and human-centric portrait of Beijing. A good story knows no borders; it can instantly bridge the distance between hearts, allowing readers and viewers around the world to find their own unique path to Beijing.”

Lei Jianhua, vice president of China National Publications Import and Export (Group) Co.,Ltd.
Lei Jianhua, vice president of China National Publications Import and Export (Group) Co.,Ltd.

Amidst deepening globalization, building platforms for international dialogue is of great significance for fostering cooperation and exchange between China and the world in areas such as trade, culture, education, and technology. By sharing Beijing’s cultural heritage and developmental achievements, the “Hello, Beijing” video series effectively sparks interest in and affinity for Chinese culture both domestically and internationally. It serves to strengthen the cultural confidence of the Chinese nation and promote Chinese culture to the world.

KuCoin Launches Stock Index Perpetual Contracts, Expanding 24/7 Cross-Asset Access

PROVIDENCIALES, Turks and Caicos Islands, March 13, 2026 /PRNewswire/ — KuCoin, a leading global crypto platform built on trust, today announced the launch of its Stock Index Perpetual Contracts, with the first batch of contracts scheduled for listing, including Tesla Index Perpetual Contract (TSLAUSDT) and MicroStrategy Index Perpetual Contract (MSTRUSDT). As traditional finance (TradFi) and crypto infrastructure continue to converge, the new product combines 24/7 trading, micro-contract entry from 1 USDT, and a risk control framework built on institutional-grade pricing, session-aware mark pricing, and EMA-based transition smoothing, offering eligible global users a more continuous, flexible, and risk-conscious tool for cross-asset allocation, while further expanding KuCoin’s cross-market derivatives infrastructure under its Trust-First strategy.


As global markets become more interconnected and increasingly event-driven, portfolio management is shifting from single-market participation toward continuous risk management across time zones and asset classes. In traditional equity markets, liquidity conditions can change sharply around market open and close, creating short-term pricing dislocations and increasing the risk of technical liquidations. KuCoin’s Stock Index Perpetual Contracts are designed to address that structural limitation by bringing equity-linked derivatives into a crypto-native, always-on trading environment.

Key features include:

  • 24/7 Trading Access – Continuous access to equity-linked contracts beyond traditional market hours.
  • Micro-Contract Entry – Positions start from as little as 1 USDT, making participation more accessible to global users.
  • Institutional-Grade Pricing Framework – Use of institutional-grade reference pricing mechanisms and session-aware mark pricing designed to better reflect underlying market conditions and reduce traders’ exposure to volatility across varying liquidity conditions.
  • EMA-Based Transition Smoothing – A pricing design intended to reduce abrupt dislocations around market open and close.

BC Wong, CEO of KuCoin, said: “Global capital markets are moving toward a new phase defined by liquidity, real-time risk management, and seamless access. We believe next-generation financial infrastructure must go beyond asset tokenization. It must also provide more reliable pricing, more continuous market access, and more disciplined risk controls. The launch of our Stock Index Perpetual Contracts reflects KuCoin’s long-term commitment to supporting the convergence of TradFi and Crypto through infrastructure built on trust.”

We will continue refining the product framework, including potential enhancements to pricing methodologies, risk management systems, and liquidity mechanisms, with the objective of supporting stable market operations and user protection. This launch not only expands KuCoin’s derivatives offering, but also reflects the core principle of its Trust-First strategy: long-term value in market innovation depends not only on broader asset access, but on the strength of the infrastructure and risk controls that support it.

About KuCoin

Founded in 2017, KuCoin is a leading global crypto platform trusted by over 40 million users across 200+ countries and regions. The platform delivers innovative digital-asset services, offering access to 1,000+ listed tokens, spot and futures trading, institutional wealth management, and a Web3 wallet.

Recognized by Forbes and Hurun, KuCoin holds SOC 2 Type II and ISO 27001:2022 certifications, underscoring its commitment to top-tier security. With AUSTRAC registration in Australia and a MiCA license in Austria, KuCoin continues expanding its regulated footprint under CEO BC Wong, building a reliable and trusted digital-asset ecosystem.

Learn more: https://www.kucoin.com/

*Important Notice:

  • These contracts are synthetic derivative products designed to track the price movements of certain publicly available equity benchmarks. They are stablecoin-settled perpetual derivative contracts and do not represent ownership of any stocks or securities, and no shares will be delivered.
  • Access to these products may not be available in certain jurisdictions and may be restricted based on applicable laws and platform compliance requirements. Trading derivatives involves significant risk, including the potential loss of your entire margin. If you have any questions, please seek independent advice. Before trading, please review the Terms of Use, Futures Services Terms, and Risk Disclosure Statements (as updated from time to time).

 

Everest Medicines’ Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

  • VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor
  • Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD
  • VIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mm
  • Potentially best-in-class durability with a favorable safety profile and no dose-limiting toxicity
  • Phase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027

SHANGHAI, March 13, 2026 /PRNewswire/ — Everest Medicines (HKEX: 1952.HK) today announced that its licensing partner, NovaBridge Biopharma (NASDAQ: NBP, “NovaBridge”), together with its subsidiary Visara, Inc. (“Visara”), reported positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Topline results show that VIS-101 produced rapid, robust and durable treatment responses in wet AMD, with potential best-in-class durability and a favorable safety profile. Wet AMD affects more than 20 million people globally[1].

Topline Data:

VIS-101 produced rapid and robust efficacy, and durable treatment responses with both 3 mg and 6 mg dose cohorts:

  • Mean improvement in Best Corrected Visual Acuity (BCVA) of >10 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters
  • Median central subfield thickness (CST) reduction of 100-150 mm
  • Potential best-in-class durability with:
    • ~two thirds of patients retreatment-free at 4 months
    • ~half of patients retreatment-free at 6 months
  • Favorable safety and no dose limited toxicity

“We congratulate our partner on the positive top-line results from the VIS-101 Phase 2a study, marking an important milestone in its clinical development. Dual VEGF-A/ANG-2 inhibition has been validated as a key approach for treating retinal vascular disease, and extending treatment durability remains a critical unmet need,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “VIS-101 has demonstrated potentially best-in-class durability, robust visual and anatomic improvements, along with a favorable safety profile, providing a strong foundation for advancing its future clinical development. With Everest’s experience in clinical development and commercialization, we look forward to bringing VIS‑101, a highly differentiated bifunctional antibody with strong commercial potential, to patients across China and Asia in the near future.”

“I am encouraged by the positive Phase 2a safety and efficacy data as it provides important proof-of-concept for VIS-101 as a potential treatment for wet AMD. The data validates VIS-101’s purpose-engineered design and gives us added confidence in its potential to deliver best-in-class durability while maximizing visual gains in the treatment of wet AMD,” said Emmett T. Cunningham, Jr., MD, PhD, MPH, Founder and Executive Chairman of Visara and Vice-Chairman of the NovaBridge Board of Directors. “The data clearly show that VIS-101 produced rapid, robust and durable treatment responses, with favorable tolerability, after three loading doses. Importantly, VIS-101 also demonstrated potential best-in-class durability, with nearly half of treatment naïve patients remaining retreatment free for more than six months following induction. Such strong clinical results provide a meaningful foundation to advance our development program, including plans to initiate a dose-determining Phase 2b study in the second half of this year, followed by a global Phase 3 program in 2027.”

On October 30, 2025, Everest Medicines entered into a collaboration agreement with Visara, under which Everest acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.

About the Randomized Phase 2a Study of VIS-101 in Wet AMD

Patient Characteristics:

The study enrolled 38 patients in China, aged 50-80 years of age with wet AMD (both treatment naïve and pre-treated). Patients were randomized 2:1 between 6mg dose (n=25) and 3 mg (n=13). Baseline characteristics were similar between both dose groups (noting a slightly higher proportion of pre-treated patients in the 6 mg dosing group).

Baseline Patient Demographics: Similar between dosing groups

Topline Phase 2a Data
Based on patients in the 6mg and 3mg dosing groups

Dose level

6 mg (n=25)

3 mg (n=13)

Total (n=38)

Patients

Age (years of age)

• Average

69.5

71.5

Gender (%)

• Male/Female

68%/32%

61.5%/38.5%

65.8%/34.2%

Mean Baseline BCVA (Letters)

54.7

52.3

53.9

Median Baseline CST (mm)

417.2

407.6

413.9

Prior Anti-VEGF Therapy (%)

•Yes/No

52%/48%

30.8%/69.2%

44.7%/55.3%

Safety: VIS-101 Demonstrated a Favorable Safety Profile With No Dose-Limiting Toxicity

  • The total treatment-related treatment emergent adverse events (TEAEs) were 0% (n=0) in the 3 mg dose and 8% (n=2) in the 6 mg dose, with 1 event each in two separate patients.

About the Randomized Phase 2a Study of VIS-101 in Wet AMD

The Phase 2a randomized study (NCT05456828) evaluated the safety and efficacy of VIS-101 (aka AM712 or ASKG712) in patients with wet AMD, including patients who were naïve to treatment or VEGF-experienced. The study enrolled a total of 38 wet AMD patients in China.

Patients were randomized 2:1 to 6mg VIS-101 (n=25) or 3 mg VIS-101 (n=13). The primary endpoint was safety and pharmacokinetics and the secondary endpoint was efficacy, measured by best corrected visual acuity (BCVA) change from baseline (assessed by early treatment diabetic retinopathy scale (ETDRS Letters), change in central subfield thickness (CST, measured in mm), and retreatment rate. Subjects were given three loading doses at weeks 0, 4 and 8, with monthly follow-up to week 36 or retreatment (based on protocol-defined Disease Activity Criteria based on BCVA, CST and wet AMD activity). Safety and efficacy endpoints were assessed at each visit including 24 weeks (6 months) after the last loading dose.

About VIS-101

VIS-101 (also known as ASKG712 or AM712), purpose-designed to be best-in-class, is a dual VEGF-A X ANG-2 inhibitor in development for the treatment of retinal vascular diseases, such as wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO), which affect more than 57 million people globally[1]. VIS-101’s bispecific, tetravalent design format provides more binding sites and increased VEGF-A and ANG-2 affinity, for rapid, robust and class-leading durable responses. VIS-101 has completed initial safety and dose-escalation studies in both the US and China and a randomized, dose-ranging 2a study in China (NCT05456828). VIS-101 is expected to advance to a dose-determining Phase 2b study in 2026, with initiation of the global Phase 3 program in 2027.

Source information:

  1. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62 (14): 26. doi: 10.1167/iovs.62.14.26

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

About Visara, Inc.

Visara is a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics. The Company is led by Co-Founder and Executive Chairman Emmett T. Cunningham, Jr., MD, PhD, MPH, a physician, innovator, entrepreneur, and investor and internationally recognized specialist in infectious and inflammatory eye disease, and Chief Medical Officer Cadmus Rich, MD, MBA, a serial entrepreneur and seasoned ophthalmic drug developer. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.

About NovaBridge

NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.

The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, Claudin 18.2 X 4-1BB bispecific antibody, and VIS-101, purpose-designed to be a best-in-class dual VEGF-A X ANG-2 inhibitor.

Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.

VIS-101 targets VEGF-A and ANG-2 to provide more rapid, robust and durable treatment responses for patients with retinal vascular diseases including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed a randomized, dose-ranging Phase 2a study for wet AMD and expects to initiate a Phase 2b study in H2 2026. NovaBridge is the majority shareholder of Visara, Inc., and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.

For more information, please visit www.novabridge.com and follow us on LinkedIn.

Forward Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

From R&D Self-Reliance to Standard Reshaping: How Chinese Brand BABI Decodes Global Photoprotection Challenges and Reconstructs Sunscreen Logic with Patented Technology

HANGZHOU, China, March 13, 2026 /PRNewswire/ — Over the past decades, the evolution of sun protection has been closely tied to humanity’s fight against skin photoaging. Despite the widespread awareness of sun protection, market feedback reveals a harsh reality: “suboptimal suncare experiences” remain a core pain point for consumers in both Asian and Western markets. This structural contradiction becomes particularly acute in extreme environments and high-intensity social scenarios:

  1. The “Protection Gap” Phenomenon: Many products boast impressive laboratory data but fail in real-world conditions of high heat and perspiration. The physical fracturing of the protective film creates invisible “blind spots,” leading to sunburn, tanning, and aging despite diligent application.
  2. Anxiety Over Skin Irritation: High concentrations of chemical UV filters are often accompanied by skin irritation, especially for those with compromised barriers. Most high-protection sunscreens inadvertently cause damage to the skin’s defensive layer.
  3. The Conflict Between Protection and Sensory Experience: To achieve SPF 50+, formulas are often forced to include large amounts of oily film-formers, resulting in a “suffocating” sensation. Consumers often need to layer sunscreen, primer, and foundation, which leads to a heavy, greasy feel and increased risks of clogged pores and breakouts.

Addressing these industry pain points, BABI (Hangzhou Blue Pool Technology Co., Ltd.), a science-led Chinese beauty brand, has introduced a systemic solution: the BABI Repairing & Tinted Whitening Sunscreen Cream 2.0. Based on invention patent ZL202411751091.2, this product fundamentally reconstructs the logic of photoprotection across two dimensions: cell biology and formulation architecture.


I. Paradigm Shift: Deep Compatibility Between High Protection and Sensitive Skin Friendliness

To resolve the conflict between “high efficiency” and “skin irritation,” the BABI Repairing & Tinted Whitening Sunscreen Cream first achieves a breakthrough in protective power. Leveraging patented technology, the product utilizes 7 chemical filters combined with physical shielding to achieve full-spectrum protection (280-400 nm). Independent testing confirms an SPF of 65 and PFA of 16. Even after a rigorous 80-minute water resistance simulation, the SPF remains stable at 36, demonstrating long-lasting protection against sweat and friction.

In addition to high protection, BABI extends its scope to the real-time neuro-sensory feedback of skin following thermal damage. The BABI Laboratory integrated the scientific breakthrough of the 2021 Nobel Prize in Physiology or Medicine: the TRPV1 channel. Widely distributed in nerve endings, this channel mediates inflammatory responses triggered by heat and UV rays. BABI innovatively introduced Kava (Piper methysticum) Extract, a clinically proven TRPV1 antagonist that acts rapidly on nerve endings to inhibit overactivation at the source. This means BABI Repairing & Tinted Whitening Sunscreen Cream creates not just a physical barrier, but a “sensory blocker” at the cellular level to alleviate burning and stinging instantly.

With a commitment to sensitive skin, the formula adheres to a “Zero-Additives” philosophy, rejecting multiple common allergens. This “post-procedure grade” soothing logic fundamentally transforms the rigid “protection-only” approach of traditional sunscreens.

II. Sensory Revolution: “Breathable” Defense via 5-Second Application and Dual-Membrane Matrix

BABI Repairing & Tinted Whitening Sunscreen Cream reshapes the user experience to combat the “heavy layering” that consumers despise.

  1. 5-Second Effortless Application: The formula features a patented Sensory Improver that significantly enhances spreadability. It achieves a “5-second application” that is lightweight and natural, concealing imperfections without the stickiness of traditional heavy makeup.
  2. The Dual-Membrane Matrix Solution: Based on patent ZL202411751091.2, BABI utilizes a multi-step emulsification process to build a Dual-Membrane Matrix system:
    • Oil Phase (PBSA Dense Barrier): Ensures high-level protection with no gaps.
    • Water Phase (Moisture-Locking Membrane): Utilizes porous microspheres to absorb excess oil, achieving a perfect balance between protection and breathability. This ensures 24-hour color integrity and prevents makeup from oxidizing or darkening.

III. Functional Minimalism: Pharmacological-Grade Dual Certifications and “Four-in-One” Consumption

Unlike single-function products, BABI Repairing & Tinted Whitening Sunscreen Cream holds dual “Special Use” certifications for “Whitening/Spot-Fading” and “Sun Protection.”

Through the synergistic system of patent ZL202411751091.2, the product achieves vertical functional integration. For whitening, it combines 2% High-Purity Niacinamide, Ethyl Ascorbic Acid (VC derivative), and Morus Alba Root Extract. Supported by the “Dual-Membrane” delivery technology, these actives bypass the skin barrier to act deeply on melanocytes. Clinical data shows that melanin levels decreased by 23.95% and skin transparency improved by 11.68% after 28 days of use, creating a comprehensive protection-and-repair mechanism.

BABI’s “Simple & Outstanding” philosophy is essentially “reductionist engineering” for modern women’s complex routines. One bottle serves as a Tone-up Cream + Sunscreen + Whitening Essence + Makeup Primer.

IV. Brand Evolution Driven by Core Technology

Founded in 2021, BABI represents the shift of Chinese beauty brands from “marketing-driven” to “hard-core technology-driven.” By translating cutting-edge research like TRPV1 into tangible products and deepening its expertise in patented processes, BABI matches the technical benchmarks of international Tier-1 brands. By innovatively integrating sun protection with base makeup, BABI effectively resolves the long-standing dilemmas that have plagued consumers, ensuring that high-performance sun protection and a superior skin feel are no longer a trade-off. Furthermore, it simultaneously addresses the demands for whitening and safety while simplifying the skincare and makeup routine, making beauty truly effortless.

The launch of the BABI Repairing & Tinted Whitening Sunscreen Cream marks the establishment of a high technical barrier in the “Sunscreen Makeup Base” sector. It provides a Chinese blueprint for the global market: how rigorous research and process breakthroughs can transform complex dermatological protection into a simple, exquisite aesthetic for every consumer.

This reflects the formidable innovative power that Chinese brands are demonstrating across various sectors as China continues its ascent. We believe that in the future, more Chinese brands will emerge to create even more extraordinary and outstanding achievements.